Maroun J A, Natale R B, Robert F
Ottawa General Hospital, Ontario, Canada.
Semin Oncol. 1988 Apr;15(2 Suppl 2):38-40.
Trimetrexate glucuronate in combination therapy with cisplatin or etoposide was evaluated in non-small cell lung cancer patients in a pilot, dose escalation study. Trimetrexate was administered intravenously together with 20 mg/m2 cisplatin or 50 mg/m2 etoposide for 5 consecutive days at an initial dose of 4 mg/m2. Courses were repeated at 3 week intervals with the trimetrexate dosage escalated according to patient tolerance. In the 12 patients treated to date, reversible myelosuppression, consisting of leukopenia and thrombocytopenia, and nonhematologic grade 1 and 2 toxicities were observed. The study is ongoing. The maximum tolerated trimetrexate dosage levels in combination therapy will be established.
在一项先导性剂量递增研究中，对非小细胞肺癌患者评估了葡糖醛酸三甲曲沙与顺铂或依托泊苷的联合治疗。三甲曲沙与20mg/m²顺铂或50mg/m²依托泊苷静脉给药，连续5天，初始剂量为4mg/m²。疗程每3周重复一次，三甲曲沙剂量根据患者耐受性递增。在迄今治疗的12例患者中，观察到由白细胞减少和血小板减少组成的可逆性骨髓抑制，以及1级和2级非血液学毒性。研究正在进行中。将确定联合治疗中三甲曲沙的最大耐受剂量水平。
